New vaccine targets 26 pneumococcal strains in early trial

NCT ID NCT06703203

Completed ⭐️ VACCINE ⭐️ Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase I/II trial tested a new 26-valent pneumococcal conjugate vaccine in 450 people aged 2 months and older. The goal was to check safety and how well the vaccine triggers an immune response compared to existing vaccines. Researchers monitored side effects and antibody levels after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 26-valent pneumococcal conjugate vaccine
What this could lead to: If successful, this vaccine could protect against more types of pneumococcal bacteria than current vaccines, potentially reducing pneumonia and ear infections.
What could go wrong: This is an early-phase trial focused on safety and immune response, not yet proven to prevent disease. Side effects like injection site pain or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL VACCINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL VACCINES

Contacts and locations

Locations

Henan Provincial Center for Disease Control and Prevention

Shangqiu, Henan, 476700, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.